Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.69 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.62 |
| ▸ | LTA4H | P09960 | 1/20 | 0.61 |
| ▸ | NPY1R | P25929 | 1/20 | 0.59 |
| ▸ | NPY2R | P49146 | 1/20 | 0.59 |
| ▸ | NPY4R | P50391 | 1/20 | 0.59 |
| ▸ | ACE | P12821 | 1/20 | 0.57 |
| ▸ | MME | P08473 | 1/20 | 0.56 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9822809 | 1.00 | FOLH1 (0.69) | FOLH1OPRD1LTA4HNPY1RNPY2R | |
| SCHEMBL29532240 | 1.00 | FOLH1 (0.69) | FOLH1OPRD1LTA4HNPY1RNPY2R | |
| Hydrochloric Acid SCHEMBL30698091 | 0.99 | FOLH1 (0.67) | FOLH1OPRD1LTA4HNPY1RNPY2R | |
| SCHEMBL29477112 | 0.97 | FOLH1 (0.66) | FOLH1OPRD1LTA4HNPY1RNPY2R | |
| SCHEMBL30683246 | 0.97 | FOLH1 (0.66) | FOLH1OPRD1LTA4HNPY1RNPY2R | |
| SCHEMBL29531738 | 0.97 | FOLH1 (0.66) | FOLH1OPRD1LTA4HNPY1RNPY2R | |
| SCHEMBL29822390 | 0.96 | FOLH1 (0.68) | FOLH1OPRD1LTA4HNPY1RNPY2R | |
| SCHEMBL3059716 | 0.94 | FOLH1 (0.62) | FOLH1OPRD1LTA4HNPY1RNPY2R | |
| SCHEMBL3059707 | 0.94 | FOLH1 (0.62) | FOLH1OPRD1LTA4HNPY1RNPY2R | |
| Trifluoroacetic Acid SCHEMBL2197916 | 0.94 | FOLH1 (0.62) | FOLH1OPRD1LTA4HNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022149634-A1 | COLOR COSMETIC COMPOSITION CONTAINING COLOR BASE AND EXTRACT ENZYMATICALLY REACTED AT LOW TEMPERATURE AND HIGH PRESSURE | (주)비엔 | 2022-07-14 | — | — | WO | claimed |
| US-12259397-B2 | Biomarkers related to organ function | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-03-25 | — | — | US | disclosed |
| WO-2024224093-A1 | DESMURAMYLPEPTIDE DIEESTERS AS NOD2 AGONISTS AND USE THEREOF | Imhotex Limited (GB) | 2024-10-31 | — | — | WO | disclosed |
| CN-116514919-A | Targeted antagonistic peptide for inhibiting tumor growth and angiogenesis and application thereof | 浙江清华长三角研究院 | 2023-08-01 | — | — | CN | disclosed |
| US-11351268-B2 | FGF21 C-terminal peptide optimization | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
| US-20200284805-A1 | BIOMARKERS RELATED TO ORGAN FUNCTION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-09-10 | — | — | US | disclosed |
| US-10634686-B2 | Biomarkers related to organ function | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2020-04-28 | — | — | US | disclosed |
| US-20160231330-A1 | BIOMARKERS RELATED TO ORGAN FUNCTION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160128961-A1 | DIETARY OMEGA-3 FATTY ACID DERIVED GLYCEROPHOSPHOLIPIDS TO TREAT NEUROPATHIC PAIN | UNIV LOMA LINDA (US) | 2016-05-12 | — | — | US | disclosed |
| WO-2015042602-A1 | BIOMARKERS RELATED TO ORGAN FUNCTION | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2015-03-26 | — | — | WO | disclosed |
| US-20150065366-A1 | Biomarkers for Bladder Cancer and Methods Using the Same | METABOLON, INC. | 2015-03-05 | — | — | US | disclosed |
| US-20140343865-A1 | Biomarkers for Kidney Cancer and Methods Using the Same | METABOLON, INC. | 2014-11-20 | — | — | US | disclosed |
| EP-2788763-A2 | BIOMARKERS FOR KIDNEY CANCER AND METHODS USING THE SAME | Metabolon, Inc. (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20140296134-A1 | METHODS AND USES FOR METABOLIC PROFILING FOR CLOSTRIDIUM DIFFICILE INFECTION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-10-02 | — | — | US | disclosed |
| EP-2776829-A1 | METHODS AND USES FOR METABOLIC PROFILING FOR CLOSTRIDIUM DIFFICILE INFECTION | The Board of Regents of The University of Texas System (US) | 2014-09-17 | — | — | EP | disclosed |
| EP-2776832-A1 | BIOMARKERS FOR BLADDER CANCER AND METHODS USING THE SAME | Metabolon, Inc. (US) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013086365-A2 | BIOMARKERS FOR KIDNEY CANCER AND METHODS USING THE SAME | METABOLON, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013070962-A1 | METHODS AND USES FOR METABOLIC PROFILING FOR CLOSTRIDIUM DIFFICILE INFECTION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013070839-A1 | BIOMARKERS FOR BLADDER CANCER AND METHODS USING THE SAME | METABOLON, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351268-B2 | FGF21 C-terminal peptide optimization | FGF23, FGFR1, FGFR3 | FOLH1 175/4885OPRD1 3847/4885LTA4H 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.